Below, we take a look at Madrigal (MDGL), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Hedge funds increased their equity-risk exposure in August. Here are the stocks they swung from long to short positions, Jefferies says.

Companies developing therapies for metabolic steatohepatitis (MASH) saw strong gains even as Novo Nordisk ($NVO) announced that its GLP-1 drug, semaglutide, demonstrated “superior improvement” in ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with ...

Madrigal Pharmaceuticals (MDGL) shares jumped after Novo Nordisk (NVO) announced that a trial showed its weight-loss drug ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...